Vaccines against Zika virus
AssigneesThe Wistar Institute of Anatomy and Biology, The Trustees of the University of Pennsylvania
InventorsDavid Weiner, Kar Muthumani
Life of this patent
Estimating the term…
Abstract
An aspect of the present invention is related to nucleic acid constructs capable of expressing a Zika antigen that elicits an immune response in a mammal against Zika virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a Zika virus, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a Zika antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal that is cross reactive against all Zika strains.
Claims17
A synthetic consensus Zika antigen, wherein the amino acid of the synthetic consensus Zika antigen is selected from the group consisting of:
- SEQ ID NO:1, an amino acid sequence that is at least 97% homologous to SEQ ID NO:1, a fragment of SEQ ID NO:1 lacking an IgE signal peptide, an amino acid sequence that is at least 97% homologous to a fragment of SEQ ID NO:1 lacking an IgE signal peptide,
- SEQ ID NO:3, an amino acid sequence that is at least 98% homologous to SEQ ID NO:3, a fragment of SEQ ID NO:3 lacking an IgE signal peptide, an amino acid sequence that is at least 98% homologous to a fragment of SEQ ID NO:3 lacking an IgE signal peptide,
- SEQ ID NO:5, an amino acid sequence that is at least 95% homologous to SEQ ID NO:5, a fragment of SEQ ID NO:5 lacking an IgE signal peptide, an amino acid sequence that is at least 95% homologous to a fragment of SEQ ID NO:5 lacking an IgE signal peptide,
- SEQ ID NO:7, an amino acid sequence that is at least 90% homologous to SEQ ID NO:7, a fragment of SEQ ID NO:7 lacking an IgE signal peptide, and an amino acid sequence that is at least 90% homologous to a fragment of SEQ ID NO:7 lacking an IgE signal peptide.
A pharmaceutical composition comprising a plasmid, wherein the plasmid comprises a nucleic acid molecule encoding a consensus Zika antigen selected from the group consisting of:
- SEQ ID NO:1, an amino acid sequence that is at least 97% homologous to SEQ ID NO:1, a fragment of SEQ ID NO:1 lacking an IgE signal peptide, an amino acid sequence that is at least 97% homologous to a fragment of SEQ ID NO:1 lacking an IgE signal peptide,
- SEQ ID NO:3, an amino acid sequence that is at least 98% homologous to SEQ ID NO:3, a fragment of SEQ ID NO:3 lacking an IgE signal peptide, an amino acid sequence that is at least 98% homologous to a fragment of SEQ ID NO:3 lacking an IgE signal peptide,
- SEQ ID NO:5, an amino acid sequence that is at least 95% homologous to SEQ ID NO:5, a fragment of SEQ ID NO:5 lacking an IgE signal peptide, an amino acid sequence that is at least 95% homologous to a fragment of SEQ ID NO:5 lacking an IgE signal peptide,
- SEQ ID NO:7, an amino acid sequence that is at least 90% homologous to SEQ ID NO:7, a fragment of SEQ ID NO:7 lacking an IgE signal peptide, and an amino acid sequence that is at least 90% homologous to a fragment of SEQ ID NO:7 lacking an IgE signal peptide,
- wherein the composition is formulated for administration of the nucleic acid molecule at a dosage selected from the group consisting of 1 mg of plasmid and 2 mg of plasmid.
A synthetic nucleic acid molecule encoding one or more Zika virus antigen, wherein the synthetic nucleic acid molecule comprises a sequence selected from the group consisting of:
- a nucleotide sequence encoding SEQ ID NO:9, a nucleotide sequence encoding an amino acid sequence that is at least 98% homologous to SEQ ID NO:9, a nucleotide sequence encoding a fragment of SEQ ID NO:
- 9 lacking an IgE signal peptide, an amino acid sequence that is at least 98% homologous to a fragment of SEQ ID NO:9 lacking an IgE signal peptide,
- a nucleotide sequence encoding SEQ ID NO:
- 11, a nucleotide sequence encoding an amino acid sequence that is at least 98% homologous to SEQ ID NO:
- 11, a nucleotide sequence encoding a fragment of SEQ ID NO:11 lacking an IgE signal peptide, an amino acid sequence that is at least 98% homologous to a fragment of SEQ ID NO:11 lacking an IgE signal peptide,
- a nucleotide sequence encoding SEQ ID NO:18, a nucleotide sequence encoding an amino acid sequence that is at least 99% homologous to SEQ ID NO:18, a nucleotide sequence encoding a fragment of SEQ ID NO:18 lacking an IgE signal peptide, an amino acid sequence that is at least 99% homologous to a fragment of SEQ ID NO:18 lacking an IgE signal peptide,
- a nucleotide sequence encoding SEQ ID NO:
- 19, a nucleotide sequence encoding an amino acid sequence that is at least 90% homologous to SEQ ID NO:19, a nucleotide sequence encoding a fragment of SEQ ID NO:19 lacking an IgE signal peptide, and an amino acid sequence that is at least 90% homologous to a fragment of SEQ ID NO:19 lacking an IgE signal peptide.
Dependencies are inferred from the claim text.